Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
News|Webcasts|June 10, 2024
Analytics and Assays Strive to Keep Pace with Innovative Modalities
Webinar Date/Time: Thu, Jun 27, 2024 11:00 AM EDT
This episode of Drug Digest explores new and emerging technologies, such as mass photometry, machine learning, and AI, and their role in the analytical space for biologic modalities.
Register Free:
Event Overview:
With the evolution of biologic modalities in the drug development pipeline, the biopharma industry understands that it must keep pace with the development and use of appropriate analytics and assays for molecule characterization, to determine product purity, safety, and efficacy, and even early on in the R&D process, where analytics are key in screening multitudes of molecules to determine viable candidates to move into the drug development phases. This episode of Drug Digest explores new and emerging technologies, such as mass photometry, machine learning, and AI, and their role in the analytical space for biologic modalities.
Key Learning Objectives:
- Introduction to new/emerging analytical technology: mass photometry
- Discuss unmet needs in biopharma analytics
- Emphasize the new understanding of biological systems from strides in research
- Discover the role digitalization plays in mapping genetic diversity
Who Should Attend:
- R&D
- Lab Analytics personnel
- Investigators
- CROs
Speaker:
Salma Jalal
Product Marketing Manager
Refeyn
As a product marketing manager at Refeyn, Salma Jalal supports customers in biopharma and the life sciences to revolutionize their analytical workflows through the use of mass photometry. She holds a PhD in Mechanobiology from the National University of Singapore and has over a decade of technical expertise in the application of microscopy techniques to study biological systems. She has a particular interest in the analysis of biologics and is very happy to discuss all things biomolecular characterization.
Register Free:
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.